Key Takeaways:
- BrainStorm Cell Therapeutics (BCLI, Financial) secures Nasdaq compliance extension until 2025.
- Promising upside of over 1,200% based on analyst price targets.
- Analyst consensus rates BCLI as "Outperform."
Nasdaq Compliance Extension
BrainStorm Cell Therapeutics (BCLI) has secured an important extension from the Nasdaq Hearings Panel, now having until June 30, 2025, to meet the necessary listing standards. This extension grants the biotech firm a critical window to advance its compliance strategies. The company's plan prominently features the launch of a Phase 3b ALS study for its innovative NurOwn® therapy alongside strategic debt reduction efforts.
Analyst Price Targets and Recommendations
Market analysts present an optimistic outlook for BrainStorm Cell Therapeutics Inc (BCLI), with 3 experts predicting an average price target of $13.84. This projection suggests a remarkable potential upside of 1,205.35% from its current market price of $1.06. The forecasts range from a low estimate of $9.00 to a high of $22.51, indicating varied yet positive expectations. For more detailed insights, please visit the BrainStorm Cell Therapeutics Inc (BCLI, Financial) Forecast page.
Brokerage Recommendations
The current consensus from one brokerage firm positions Brainstorm Cell Therapeutics Inc's (BCLI) as "Outperform," with an average recommendation score of 2.0. In this rating system, a score of 1 indicates a Strong Buy, whereas 5 denotes a Sell recommendation. This rating further underscores the firm's favorable standing among analysts.
